ATC code C03

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

A section of the Anatomical Therapeutic Chemical Classification System.

C Cardiovascular system

C03A Low-ceiling diuretics, thiazides

C03AA Thiazides, plain

C03AA01 Bendroflumethiazide

C03AA02 Hydroflumethiazide

C03AA03 Hydrochlorothiazide

C03AA04 Chlorothiazide

C03AA05 Polythiazide

C03AA06 Trichlormethiazide

C03AA07 Cyclopenthiazide

C03AA08 Methyclothiazide

C03AA09 Cyclothiazide

C03AA13 Mebutizide

C03AB Thiazides and potassium in combination

C03AB01 Bendroflumethiazide and potassium

C03AB02 Hydroflumethiazide and potassium

C03AB03 Hydrochlorothiazide and potassium

C03AB04 Chlorothiazide and potassium

C03AB05 Polythiazide and potassium

C03AB06 Trichlormethiazide and potassium

C03AB07 Cyclopenthiazide and potassium

C03AB08 Methyclothiazide and potassium

C03AB09 Cyclothiazide and potassium

C03AH Thiazides, combinations with psycholeptics and/or analgesics

C03AH01 Chlorothiazide, combinations

C03AH02 Hydroflumethiazide, combinations

C03AX Thiazides, combinations with other drugs

C03AX01 Hydrochlorothiazide, combinations

C03B Low-ceiling diuretics, excluding thiazides

C03BA Sulfonamides, plain

C03BA02 Quinethazone

C03BA03 Clopamide

C03BA04 Chlortalidone

C03BA05 Mefruside

C03BA07 Clofenamide

C03BA08 Metolazone

C03BA09 Meticrane

C03BA10 Xipamide

C03BA11 Indapamide

C03BA12 Clorexolone

C03BA13 Fenquizone

C03BA82 Clorexolone, combinations with psycholeptics

C03BB Sulfonamides and potassium in combination

C03BB02 Quinethazone and potassium

C03BB03 Clopamide and potassium

C03BB04 Chlortalidone and potassium

C03BB05 Mefruside and potassium

C03BB07 Clofenamide and potassium

C03BD Xanthine derivatives

C03BD01 Theobromine

C03BK Sulfonamides, combinations with other drugs

C03BX Other low-ceiling diuretics

C03BX03 Cicletanine

C03C High-ceiling diuretics

C03CA Sulfonamides, plain

C03CA01 Furosemide

C03CA02 Bumetanide

C03CA03 Piretanide

C03CA04 Torasemide

C03CB Sulfonamides and potassium in combination

C03CB01 Furosemide and potassium

C03CB02 Bumetanide and potassium

C03CC Aryloxyacetic acid derivatives

C03CC01 Etacrynic acid

C03CC02 Tienilic acid

C03CD Pyrazolone derivatives

C03CD01 Muzolimine

C03CX Other high-ceiling diuretics

C03CX01 Etozolin

C03D Potassium-sparing agents

C03DA Aldosterone antagonists

C03DA01 Spironolactone

C03DA02 Potassium canrenoate

C03DA03 Canrenone

C03DA04 Eplerenone

C03DB Other potassium-sparing agents

C03DB01 Amiloride

C03DB02 Triamterene

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Potassium-sparing diuretic refers to diuretic drugs that do not promote the secretion of potassium into the urine. They are used as adjunctive therapy, together with other drugs, in the treatment of hypertension and management of congestive heart failure.

Mechanism of action

Potassium-sparing diuretics decrease sodium reabsorption at collecting tubules, inducing diuresis; decrease activity of aldosterone at collecting tubules.

Indications

Potassium-sparing diuretics are generally used in combination with other diuretic drugs (e.g. loop diuretics) that would otherwise tend to lower the potassium levels to potentially dangerous low levels (hypokalemia). The combination therefore helps maintain a normal reference range for potassium.

Side effects

On their own this group of drugs may raise potassium levels beyond the normal range, termed hyperkalemia, which risks potentially fatal arrhythmias.

Chemical structure

Potassium-sparing diuretics do not share any obvious chemical similarities, except for the steroid-structure of the aldosterone antagonists. Those in clinical use include:

External links

Potassium+Sparing+Diuretics at the US National Library of Medicine Medical Subject Headings (MeSH)

References

Block JH, Beale JM. “Organic Medicinal and Pharmaceutical Chemistry” 11th edition. Lippincott Williams & Wilkins. 2004.

Template:SIB

Template:WikiDoc Sources

C03E Diuretics and potassium-sparing agents in combination

C03EA Low-ceiling diuretics and potassium-sparing agents

C03EA01 Hydrochlorothiazide and potassium-sparing agents

C03EA02 Trichlormethiazide and potassium-sparing agents

C03EA03 Epitizide and potassium-sparing agents

C03EA04 Altizide and potassium-sparing agents

C03EA05 Mebutizide and potassium-sparing agents

C03EA06 Chlortalidone and potassium-sparing agents

C03EA07 Cyclopenthiazide and potassium-sparing agents

C03EA12 Metolazone and potassium-sparing agents

C03EA13 Bendroflumethiazide and potassium-sparing agents

C03EA14 Butizide and potassium-sparing agents

C03EB High-ceiling diuretics and potassium-sparing agents

C03EB01 Furosemide and potassium-sparing agents

C03EB02 Bumetanide and potassium-sparing agents